Discover
IMU-935 / ImmunicIMU-935: Initiation of PART B of P1 trial in healthy volunteers in Q3 2020 (Immunic Therapeutics) - May 28, 2020 - R&D Day: Initiation of PART C of P1 trial for moderate-to-severe psoriasis in H2 2020 [Screenshot]
llllllllll brepocitinib (PF-06700841) / PfizerA Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis (clinicaltrials.gov) - May 26, 2020 - P2b; N=218; Active, not recruiting; Sponsor: Pfizer; Recruiting --> Active, not recruiting
IMU-935 / ImmunicIMU-935: PK data from P1 trial for healthy volunteers in Q2 2020 (Immunic Therapeutics) - May 29, 2020 - Company Overview: Data from SAD and MAD parts of P1 trial for healthy volunteers later in 2020 [Screenshot]
IMU-935 / ImmunicIMU-935: Data from PART C of P1 trial for psoriasis in 2021 (Immunic Therapeutics) - May 29, 2020 - R&D Day [Screenshot]
Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Hakko Kirin; Stelara (ustekinumab) / J&JEMBRACE 1: Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - May 28, 2020 - P3; N=120; Not yet recruiting; Sponsor: LEO Pharma; Trial completion date: Aug 2023 --> Nov 2023; Initiation date: Jun 2020 --> Sep 2020; Trial primary completion date: Oct 2022 --> Jan 2023
